Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial
Thyroid tumors: Some GLP-1 medications carry a warning about a potential risk of thyroid C-cell tumors
Clinical trials have consistently shown that patients treated with semaglutide GLP-1 experience significant weight loss compared to those receiving a placebo, often exceeding the results achieved with other anti-obesity medications
Participants achieved A1C reductions of up to 2.0% at 40 weeks, with no weight loss plateau observed
After PSM, 81,152 participants remained in the SGLT2i group, and 20,288 participants remained in the GLP1RA group (Fig
